Feature

Retrieval and Analysis of Particulate Debris After Saphenous Vein Graft Intervention

*John G. Webb, MD, *Ronald G. Carere, MD, **Renu Virmani, MD, †Donald Baim, MD, ††Paul S. Teirstein, MD, §Patrick Whitlow, MD, §§Colleen McQueen, RN, **Frank D. Kolodgie, PhD, *Elizabeth Buller, RN, *Arthur Dodek, MD, ‡G.B. John Mancini, MD, ‡‡Stephen Oesterle, MD
*John G. Webb, MD, *Ronald G. Carere, MD, **Renu Virmani, MD, †Donald Baim, MD, ††Paul S. Teirstein, MD, §Patrick Whitlow, MD, §§Colleen McQueen, RN, **Frank D. Kolodgie, PhD, *Elizabeth Buller, RN, *Arthur Dodek, MD, ‡G.B. John Mancini, MD, ‡‡Stephen Oesterle, MD
ABSTRACT: Objectives. This study was designed to evaluate the composition and quantity of particulate debris resulting from vein graft intervention. Background. Distal embolization and “no reflow” are frequent and important complications resulting from angioplasty of diseased saphenous vein grafts. Little is known about the composition and quantity of embolic particulate debris associated with vein graft intervention, and no intervention has been shown to protect against its clinical consequences. Methods. A catheter system, designed to contain, retrieve and protect against distal embolization of this material, was evaluated during 27 percutaneous interventional saphenous vein graft procedures. Clinical, angiographic and pathologic analyses were performed. Results. The duration of distal graft occlusion required to allow intervention and subsequent debris removal was 150 ± 54 seconds, decreasing as experience was gained. Thrombolysis in Myocardial Infarction (TIMI) trial flow grade increased from 2.6 ± 0.8 to 3.0 ± 0.0. Creatine kinase (CK) rose above normal in 3 patients (11.1%) exceeding 3x normal in one (3.7%) resulting in the diagnosis of non-Q wave myocardial infarction. Particulate material was identified following 21 of 23 procedures suitable for analysis. Particle size was 204 ± 57 µm in the major axis and 83 ± 22 µm in the minor axis. Particles consisted predominantly of soft acellular atheromatous material, such as that typically found under a fibrous cap. Semiquantitative analysis suggested that the quantity of particulate material was less following stenting than following balloon dilation. Conclusions. Particulate matter is commonly present following routine angioplasty and stenting of saphenous vein grafts. Containment, retrieval and analysis of this particulate debris are all feasible. Comparison to prior clinical experience is limited by small sample size. However, to the extent that these particles may contribute to distal embolization, no-reflow and infarction, such a system may contribute to the reduction of complications following vein graft intervention. A limitation of coronary bypass surgery has been the relatively rapid progression of atheromatous disease in aortocoronary saphenous vein grafts.1 More than one-half of such grafts have failed by 10 years, and the risk of repeat surgery is significantly greater than that of the initial procedure.2,3 Interventional management of saphenous vein graft disease is limited by distal embolization4,5 and “no-reflow”,6–10 which may arise from disruption of soft, friable atherosclerotic plaque and adherent thrombus.11,12 The reported incidence of distal embolization following balloon angioplasty ranges from 2–42%, contributing to substantial morbidity.4,6,13–17 Recognized predictors of distal embolization and infarction include the presence of diffuse disease, plaque volume and thrombus.17 Little information is available about the composition of this particulate material, and no method has been shown to prevent distal embolization. We describe a catheter system designed to contain and retrieve this particulate material, the clinical and angiographic outcome following application of this system and analysis of the composition of this particulate material. Methods Experimental protocol. Between July 1997 and April 1998, a total of 22 consecutive eligible patients underwent 27 vein graft angioplasty procedures utilizing a device (PercuSurge, Sunnyvale, California) designed to contain and retrieve potentially embolic particulate material. Patients were considered eligible if they were between 35 and 85 years of age with evidence of ischemia and had a > 70% diameter stenosis = 1 in a saphenous vein graft 3.5–5 mm in diameter. Exclusion criteria included myocardial infarction Device description. The particulate containment and retrieval system consists of several components, as shown in Figure 1. The 210 cm angioplasty wire is constructed of 0.014´´ nitinol hypotube with a 35 mm radiopaque, shapeable, steerable tip. Incorporated in the distal wire is a 5.5-mm-long elastomeric balloon with a 0.41–0.43´´ crossing profile and available inflated diameter of 3.5–5.0 mm (Figure 2). A detachable inflation adapter accesses the hypotube lumen by displacing a small seal, allowing inflation of the balloon. An aspiration catheter (Export, PercuSurge) with an internal lumen diameter of 0.040´´ allows removal of particulate debris before deflation of the occlusive balloon. The 135-cm-long aspiration catheter has a 35-cm-long distal monorail wire lumen and an external diameter of 0.072´´. The occlusion balloon was advanced through the graft and distal to the stenosis. The inflation adapter was temporarily attached and the distal occlusion balloon inflated. Following removal of the inflation adapter, intervention was performed in a standard manner utilizing the hypotube as the angioplasty guidewire (Figure 3). After removal of the interventional device, the aspiration catheter was advanced over the wire to the occlusion balloon. A 20 ml locking syringe was attached to the aspiration catheter to generate a vacuum and to serve as the collection chamber. Following manual aspiration, the inflation adapter was again attached and the distal occlusion balloon deflated, thus allowing coronary flow to resume. Angioplasty procedure. Angioplasty was performed utilizing 8 Fr guides with an internal lumen of 0.086´´ and monorail balloon catheters (Boston Scientific, Galway, Ireland). Initial patients underwent balloon predilation prior to stent deployment. Subsequent patients later underwent primary stenting without predilation. Nir (Boston Scientific, Jerusalem, Israel), biliary Palmaz-Schatz (Johnson & Johnson Interventional Systems, Warren, New Jersey), Multi-Link (Guidant Corporation, Temecula, California), and BeStent (Medtronic Instent, Haifa, Israel) stents measuring 9–35 mm in length were implanted. Stents were dilated utilizing the initial deployment balloon inflated to at least 12 atmospheres with a goal balloon-to-reference segment ratio of > 1.1:1. Patients were pretreated with aspirin 325 mg daily. Ticlopidine 500 mg daily was initiated following the procedure and continued for two weeks. Heparin was administered to achieve an activated clotting time exceeding 300 seconds and routinely discontinued immediately on completion. Abciximab was utilized in four patients. Dextran, dipyridamole, warfarin, thrombolytics, calcium channel blockade and nitroglycerin were not routinely utilized. Angiographic assessment. Angiograms, performed in orthogonal views at baseline and after the intervention, were quantitatively analyzed at an independent core laboratory (Vancouver General Hospital). Thrombus was judged to be present if contrast angiography demonstrated an intraluminal filling defect or an abrupt vessel cut-off. “No-reflow” was defined as a new, severe reduction in coronary flow to TIMI grade 0 or 1 not due to local thrombus, spasm or dissection, implying obstruction at the level of the distal small vessels.18 Distal embolization was diagnosed when there was a filling defect, no reflow, or an abrupt cut-off in a distal coronary artery branch. Pathologic assessment. Vein graft aspirate was collected in glass tubes containing EDTA-citrate buffer and transported on ice. Samples were centrifuged, the plasma removed and the pellet resuspended in incomplete Hank’s Balanced Salt Solution without calcium and magnesium. Erythrocytes were lysed with 1% saponin. The reaction was stopped by calcium gluconate, and samples were then centrifuged, resuspended and the lysis step repeated. The remaining material was fixed in 10% neutral buffered formalin or glutaraldehyde and processed for light microscopy and scanning electron microscopy. Semiquantitative analysis was performed on 4-µm-thick paraffin-embedded sections stained with hematoxylin and eosin. Samples were considered to have maximal tissue if some atherosclerotic material was present in every high power field of the section of the precipitate, moderate if every other field showed some atherosclerotic material, and minimal when only sparse material was evident. Particle size was measured from scanning electron micrographs containing a calibrated bar. The major and minor lengths and area of each particle were determined using computer software (IP Labs, Signal Analytics, Vienna, Virginia). Clinical outcomes. Total creatine kinase (CK) and creatine kinase, MB fraction (CK-MB) were measured before angioplasty, 8 hours and 16 hours postangioplasty. an electrocardiogram (ECG) was obtained before angioplasty, immediately following angioplasty, if chest discomfort recurred and the following morning. Myocardial infarction was defined as an elevation of CK to > 3 times normal associated with elevation of CK-MB.19 Q-wave infarction was diagnosed in the presence of new Q-waves in two contiguous leads. Clinical follow-up was obtained prospectively, by chart review and by telephone. Statistical analysis. Results are reported as means ± SEM. Comparisons between angiographic measurements were made with paired t-tests. Group comparisons were performed by factorial ANOVA (STATVIEW 4.5, Abacus Concepts, San Francisco, California) and analyzed simultaneously with post hoc testing by the Scheffé procedure. Statistical significance was defined as p Clinical outcome. All 27 procedures were technically successful, as shown in Figure 4. A total of 37 lesions were treated with implantation of 36 stents. No patient developed new Q-waves, required cardiac surgery or died. Creatine kinase remained normal (Angiographic results. Qualitative and quantitative angiographic results are presented in Table 2. In no patient was the occlusion balloon associated with visible damage to the distal vessel. Follow-up angiography performed in nine patients at 5 ± 3 months found restenosis (stenosis > 50%) in four grafts, TIMI flow grade 2.9 ± 0.4 and no evidence of new disease at the site of distal occlusion. Pathologic assessment. A total of 49 aspirations were suitable for analysis. Particulate material was retrieved from 21 of 23 procedures. Light microscopy revealed that the particles consisted predominantly of necrotic core with cholesterol clefts, lipid-rich macrophages and fibrin material (Figure 5). Fibrous caps and smooth muscle cells were identified, but these appeared relatively sparse. This suggested the material consisted primarily of the soft acellular atheromatous material typically found under the fibrous cap (Table 3). Scanning electron microscopy found a particle size of 204 ± 57 µm (range, 8–3,427 µm) in the major axis and 83 ± 22 µm in the minor axis (Figure 6). Semiquantitative analysis of aspirates, as shown in Table 3, found both balloon angioplasty and stenting were associated with recovery of particulate debris. However, particulate material was significantly greater following balloon predilation than subsequent stenting (p = 0.43). Direct stenting without balloon predilation was associated with less particulate material than seen with balloon predilation alone and less than that associated with the combination of balloon predilation and subsequent stenting. Although suggestive, numbers were small and not statistically significant. Discussion Study findings and implications. The principal finding of our study is that embolic atherothrombotic particulate matter is commonly liberated during angioplasty and stenting of saphenous vein grafts. This particulate matter may play a role in the pathogenesis of distal embolization, no-reflow and infarction following vein graft intervention. Particulate retrieval procedure. The GuardWire system is compatible with routine angioplasty procedures and is capable of containing and then retrieving particulate debris. Event rates, including CK elevation (11.1%) and non-Q wave myocardial infarction (3.7%), were lower than generally reported following vein graft angioplasty without such protection.17,19–21 In no case was vessel damage seen as a result of inflation of the distal occlusive balloon, and late development of a stenosis at the site of distal occlusion was not apparent. Ischemic times required for distal occlusion and aspiration during angioplasty were well tolerated, averaging 2.5 minutes. Initial patients in this series underwent a staged procedure with graft aspiration and deflation of the distal occlusion balloon following predilation and stent deployment. Because these brief periods of graft occlusion were well tolerated in early cases, a single-stage approach subsequently proved feasible and desirable. Stenting of vein grafts. All patients in this series underwent stent implantation. Initial studies of the Palmaz-Schatz stent in focal vein graft stenoses reported transient no-reflow in approximately 10% of procedures22 and a 10–12% incidence of non-Q wave myocardial infarction.22–26 The Saphenous Vein De Novo Trial27 compared the Palmaz-Schatz stent to balloon angioplasty and found a trend toward less non-Q wave infarction (2% versus 7%; p = 0.1). In one series, the Palmaz-Schatz biliary stent was associated with distal embolization in 23% of patients and non-Q wave infarction in 44%.28 De Jaegere29 reported an 11% incidence of in-hospital infarction, urgent surgery or death in a group of patients primarily treated with the Wallstent. Limited experience has been reported with the Wallstent,29–31 Wiktor,32 and Gianturco-Roubin stents33 and covered stents.34 Cardiac enzymes. Cardiac enzymes rise in 5–20% of patients following percutaneous coronary interventions in native vessels.19 The reported frequency of enzyme elevation following vein graft intervention is generally higher17,19–21,34,35 in contrast to the 11.1% incidence of CK elevation and 3.7% incidence of non-Q wave infarction (CK > 3 times normal) in this study. There is some debate as to a cause-effect relationship between elevations of CK, CK-MB and adverse late clinical outcome.19 Comparison to alternative strategies. Direct aspiration has been reported of angiographically visible thrombus from vein grafts utilizing standard angioplasty guiding catheters36–38 and specially constructed thrombo-suction devices.39,40 Experience with directional atherectomy, laser and rotablator in vein grafts has been disappointing.41–45 Transluminal extractional atherectomy (InterVentional Technologies, Bellevue, Washington) may reduce cardiac enzyme release following graft intervention; however, experience has been variable, and distal embolization remains a concern.13,46–50 Fibrinolytic drugs have been advocated as adjuncts to vein graft intervention, and local fibrinolysis has been utilized to debulk intragraft thrombus. However, reduced embolic complications have not been demonstrated.51,52 Glycoprotein IIb/IIIa inhibition may be desirable.53,54 In the EPIC trial, abciximab was associated with a reduction in distal embolization and a nonsignificant trend (14% versus 5%) toward reduced infarction in the subgroup of patients undergoing vein graft intervention.55 However, when results of both the EPIC and EPILOG trials were combined, no benefit was found in patients undergoing vein graft intervention.53 Although secondary platelet activation by particulate matter is possible, the large amount of particulate atheroembolic material demonstrated in our study suggests a limited role for antiplatelet therapies in the prevention of distal embolization in saphenous grafts. Implications for stenting. The quantity of particulate debris retrieved after balloon predilation was greater than that retrieved after subsequent stent deployment (Table 3). This supports conjecture that the screen-like configuration of stents may entrap friable material, reducing the likelihood of dislodgement and embolization.27,50 An antiembolic role for stents may have implications for optimal stent design. Greater surface coverage might be desirable for stents designed for use in vein grafts. The quantity of particulate matter retrieved in patients who underwent balloon predilation and subsequent stenting may be greater than that retrieved in patients undergoing direct stenting without predilation. This finding suggests that balloon predilation before stenting may increase embolic debris50 and that direct stent implantation without predilation may be desirable where possible. However, all interventions were associated with the recovery of particulate debris. Study limitations. This single-center study is limited by small size, by limited angiographic follow-up, semiquantitative analysis of particulate material and the lack of a randomized control group. Comparison with prior studies must be made with caution. The possibility that some of the aspirated debris might have been removed directly from the graft wall, as opposed to the lumen, cannot be excluded, although the direct effect of the aspiration catheter on the vein graft wall would be comparable to passage of other catheters commonly used during coronary interventions. There remains the potential risk for graft embolization during passage of the device before distal occlusion or to incomplete removal of debris. Further clinical trials will require direct comparison with routine vein graft intervention. Finally, embolic atherothrombotic particulate matter is commonly present within saphenous vein grafts following routine angioplasty and stenting. Containment and retrieval of embolic particulate matter is feasible, and further trials of protections devices appear warranted. This particulate matter may play a role in the pathogenesis of distal embolization, no-reflow and infarction following vein graft intervention.
References
1. Bourassa M, Fisher L, Campeau L, et al. Long-term fate of bypass grafts: The Coronary Artery Surgery Study (CASS) and Montreal Heart Institute experiences. Circulation 1985;72:V71–V77. 2. Campeau L, Enjalbert M, Lesperance J, et al. The relation of risk factors to the development of atherosclerosis in saphenous vein bypass grafts and the progression of disease in the native circulation. N Engl J Med 1984;311:1329–1332. 3. Hamm C, Reimers J, Ischinger T, et al. A randomized study of coronary angioplasty compared with bypass surgery in patients with multivessel disease. N Engl J Med 1994;1037–1041. 4. Trono R, Sutton C, Hollman J, et al. Multiple myocardial infarctions associated with atheromatous emboli after PTCA of saphenous vein grafts. Cleve Clin J 1989;56:581–584. 5. Waller B, Rothbaum D, Gorfinkel H, et al. Morphologic observations after percutaneous transluminal balloon angioplasty of early and late aortocoronary saphenous vein grafts. J Am Coll Cardiol 1984;4:784–792. 6. Kaplan B, Benzuly K, Kinn J, et al. Treatment of no-reflow in degenerated saphenous vein graft interventions: Comparison of intracoronary verapamil and nitroglycerin. Cathet Cardiovasc Diagn 1996;39:113–118. 7. Baim D, Carrozza JJ. Understanding the “no-reflow” problem. Cathet Cardiovasc Diagn 1996;1:7–8. 8. Piana R, Paik G, Moscucci M, et al. Incidence and treatment of “no-reflow” after percutaneous coronary interventions. Circulation 1994;89:2514–2518. 9. Abbo K, Dooris M, Glazier S, et al. Features and outcome of no-reflow after percutaneous coronary intervention. Am J Cardiol 1995;89:778–782. 10. Morishima I, Sone T, Mokuno S, et al. Clinical significance of no-reflow phenomenon observed on angiography after successful treatment of acute myocardial infarction with percutaneous transluminal coronary angioplasty. Am Heart J 1995;2:239–243. 11. Walts A, Fishbein M, Sustaite H, Matloff J. Ruptured atheromatous plaques in saphenous vein coronary bypass grafts: A mechanism of acute, thrombotic, late graft occlusion. Circulation 1982;65:197–201. 12. Mautner S, Mautner G, Hunsberger S, Roberts W. Comparison of atherosclerotic plaques in saphenous veins used as aortocoronary bypass conduits with plaques in native coronary artery in the same men. Am J Cardiol 1992;70:1380–1387. 13. Hong M, Popma J, Pichard A, et al. Clinical significance of distal embolization after transluminal extraction atherectomy in diffusely diseased saphenous vein bypass grafts. Am Heart J 1994;127:1496–1503. 14. Altmann D, Racz M, Battleman D, et al. Reduction in angioplasty complications after the introduction of coronary stents: Results from a consecutive series of 2,242 patients. Am Heart J 1996;132:503–507. 15. Webb J, Myler R, Shaw R, et al. Coronary angioplasty after coronary bypass surgery: Initial results and late outcome in 422 patients. J Am Coll Cardiol 1990;116:812–820. 16. Platko W, Hollman J, Whitlow P, Franco I. Percutaneous transluminal coronary angioplasty of saphenous vein graft stenosis: Long-term follow-up. J Am Coll Cardiol 1989;14:1645–1650. 17. Liu M, Douglas JJ, Lembo N, et al. Angiographic predictors of a rise in serum creatine kinase (distal embolization) after balloon angioplasty of saphenous vein coronary angioplasty. Am J Cardiol 1993;72:514–517. 18. TIMI Study Group. The Thrombolysis in Myocardial Infarction (TIMI) trial: Phase I findings. N Engl J Med 1995;312:932–936. 19. Califf R, Abdelmeguid A, Kuntz R, et al. Myonecrosis after revascularization procedures. J Am Coll Cardiol 1998;31:241–251. 20. Tardiff B, Mabe B, Wildermann N, et al. Predictors of myocardial infarction (MI) with percutaneous revascularization in a large multi-center population (Abstr). J Am Coll Cardiol 1997;88:I-277A. 21. Moscucci M, Cohen D, Kugelmass A, et al. Should small (non-Q wave) myocardial infarction be considered “major” or “minor” complications after otherwise successful stenting or atherectomy? (Abstr). Circulation 1993;88:I-548. 22. Friedrich S, Davis S, Kuntz R, et al. Investigational use of the Palmaz-Schatz biliary stent in large saphenous vein grafts. Am J Cardiol 1993;71:439–441. 23. White C, Ramee S, Collins T, et al. Placement of “biliary” stents in saphenous vein coronary bypass grafts. Cathet Cardiovasc Diagn 1993;30:91–95. 24. Savage M, Fischman D, Schatz R, for the Palmaz-Schatz Stent Study Group. Long-term angiographic and clinical outcome after implantation of balloon-expandable stents in the native coronary circulation. J Am Coll Cardiol 1994;24:1207–1212. 25. Fenton S, Fischman D, Savage M, et al. Long-term angiographic and clinical outcome after implantation of balloon-expandable stents in aortocoronary saphenous vein grafts. Am J Cardiol 1994;74:1187–1191. 26. Plana R, Moscucci M, Cohen D, et al. Palmaz-Schatz stenting for treatment of focal vein graft stenosis: Immediate results and long-term outcome. J Am Coll Cardiol 1994;23:1296–1304. 27. Savage M, Douglas JJ, Fischman D, et al. Stent placement compared with balloon angioplasty for obstructed coronary bypass grafts. N Engl J Med 1997;337:740–747. 28. Kramer B. Optimal therapy for degenerated saphenous vein graft disease. J Invas Cardiol 1995;7:14–20. 29. de Jaegere P, van Domburg R, Feyter P, et al. Long-term clinical outcome after stent implantation in saphenous vein grafts. J Am Coll Cardiol 1996;28:89–96. 30. Itoh A, Hall P, Maiello L, et al. Implantation of the peripheral Wallstent for diffuse lesions in coronary arteries and grafts. Cathet Cardiovasc Diagn 1996;37:322–330. 31. Eeckhout E, Goy J, Stauffer J, et al. Endoluminal stenting of narrowed saphenous vein grafts: Long-term clinical and angiographic follow-up. Cathet Cardiovasc Diagn 1994;33:139–146. 32. Vaishnav S, Aziz S, Layton C. Clinical experience with the Wiktor stent in native arteries and coronary bypass grafts. Br Heart J 1994;72:288–293. 33. Dorros G, Bates M, Iyer S, et al. The use of Gianturco-Roubin flexible metallic coronary stents in old saphenous vein grafts: In-hospital outcome and 7-day angiographic patency. Eur Heart J 1994;11:1456–1462. 34. Reifart N, Storger H, Schwartz F, Rabe A. PTCA of degenerated vein grafts: Experience of two periods (1992–3 and 1996–7) in 780 patients. Indian Heart J 1998;50:62–66. 35. Altmann D, Popma J, Hong M, et al. CPK-MB elevation after angioplasty of saphenous vein grafts (Abstr). J Am Coll Cardiol 1993;21:232A. 36. Cunningham J, Ling F. Transcatheter aspiration of atheroma through saphenous vein graft stents. Cathet Cardiovasc Diagn 1996;39:258–261. 37. Dooris M, Grines C. Successful reversal of cardiogenic shock precipitated by saphenous vein graft distal embolization using aspiration thrombectomy. Cathet Cardiovasc Diagn 1994;33:267–271. 38. Khoury A, Donohue T, Kern M. Aspiration of coronary thrombus during angioplasty for postmyocardial infarction ischemia. Cathet Cardiovasc Diagn 1995;35:132–135. 39. van den Boss A, van Ommen V, Corbeij H. A new thrombosuction catheter for coronary use: Initial results with clinical and angiographic follow-up in seven patients. Cathet Cardiovasc Diagn 1997;40:192–197. 40. Drasler W, Jenson M, Wilson G, et al. Rheolytic catheter for percutaneous removal of thrombus. Radiology 1992;182:263–267. 41. Bittl J, Sanborn T, Yardley D, et al. Predictors of outcome of percutaneous excimer laser coronary angioplasty of saphenous vein bypass graft lesions: The Percutaneous Excimer Laser Coronary Angioplasty Registry. Am J Cardiol 1994;74:144–148. 42. Cowley M, DiSciascio G. Directional coronary atherectomy for saphenous vein graft disease. Cathet Cardiovasc Diagn 1993;(Suppl 1):10–16. 43. Pomerantz R, Kuntz R, Carrozza J. Acute and long-term outcome of narrowed saphenous venous grafts treated by endoluminal stenting and directional atherectomy. Am J Cardiol 1992;70:161–167. 44. Kaufman U, Garratt K, Vliestra R, Holmes D. Transluminal atherectomy of saphenous vein aortocoronary bypass grafts. Am J Cardiol 1990;65:1430–1433. 45. Holmes DJ, Topol E, Califf R, et al. A multicenter, randomized trial of coronary angioplasty versus directional atherectomy for patients with saphenous vein bypass grafts. Circulation 1995;91:1966–1974. 46. Misumi K, Matthews R, Sun G, et al. Reduced distal embolization with transluminal extraction atherectomy compared with balloon angioplasty for saphenous vein graft disease. Cathet Cardiovasc Diagn 1996;39:246–251. 47. Safian R, Grines D, May M, et al. Clinical and angiographic results of transluminal extraction atherectomy in saphenous vein bypass grafts. Circulation 1994;89:302–312. 48. Meany T, Leon T, Kramer B, et al. Transluminal extraction catheter for the treatment of diseased saphenous vein grafts: A multicenter experience. Cathet Cardiovasc Diagn 1995;34:112–120. 49. Twidale N, Barth C, Kipperman R, et al. Acute results and long-term outcome of transluminal extraction catheter atherectomy for saphenous vein graft stenoses. Cathet Cardiovasc Diagn 1994;31:187–191. 50. Braden G, Xenopoulos N, Young T, et al. Transluminal extraction catheter atherectomy followed by immediate stenting in treatment of saphenous vein grafts. J Am Coll Cardiol 1997;30:657–663. 51. Glazier J, Kiernan F, Bauer H, et al. Treatment of thrombotic saphenous vein bypass grafts using local infusion therapy with the Dispatch catheter. Cathet Cardiovasc Diagn 1997;41:261–267. 52. Hartmann J, McKeever I, Statmatao N, et al. Recanalization of chronically occluded aortocoronary saphenous vein bypass grafts with long-term, low-dose direct infusion of urokinase (ROBUST): A serial trial. J Am Coll Cardiol 1996;27:60–66. 53. Tcheng J. Glycoprotein IIb/IIIa receptor inhibitors: Putting the EPIC, IMPACT II, RESTORE, and EPILOG trials into perspective. Am J Cardiol 1996;78:35–40. 54. van de Werf F. More evidence for a beneficial effect of platelet glycoprotein IIb/IIIa blockade during coronary interventions: Latest results from the EPILOG and CAPTURE trials. Eur Heart J 1996;17:325–326. 55. Mak K, Challapalli R, Eisenberg M, et al. Effect of platelet glycoprotein IIb/IIIa receptor inhibition on distal embolization during percutaneous revascularization of aortocoronary saphenous vein grafts. Am J Cardiol 1997;80:985–988.